| CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE |
KUALA LUMPUR, MALAYSIA, May 15, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines, today announced its first quarter financial results and provided a business update. |
globenewswire.com |
2025-05-15 04:50:00 |
Czytaj oryginał (ang.) |
| CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT |
BERKELEY HEIGHTS, NJ, May 07, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines, today announced that it expects to implement a 1-for-16 reverse stock split on its shares of common stock effective May 12, 2025, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the shares of common stock will continue on The Nasdaq Capital Market under the symbol “CYCC”. The new CUSIP number for the shares of common stock following the reverse stock split is 23254L884. |
globenewswire.com |
2025-05-07 13:00:00 |
Czytaj oryginał (ang.) |
| CYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE EXCHANGE AGREEMENT TO MAKE FITTERS SDN. |
KUALA LUMPUR, MALAYSIA, May 06, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”) today announced that it entered into an Exchange Agreement with FITTERS Diversified Berhad (9318.KL; “FITTERS”), an investment holding company engaged, through its subsidiaries, in the business of the sale of fire safety materials, equipment and fire prevention systems, “Waste-To-Resource” services and real estate development and construction. |
globenewswire.com |
2025-05-06 10:00:00 |
Czytaj oryginał (ang.) |
| Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update |
BERKELEY HEIGHTS, N.J., April 02, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines, today announced fourth quarter financial results and provided a business update. |
globenewswire.com |
2025-04-02 20:05:00 |
Czytaj oryginał (ang.) |
| Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock |
KUALA LUMPUR, Malaysia, March 24, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicine, today announced that it has entered into a securities purchase agreement for the sale of its convertible Series E Preferred Stock (“Preferred Stock”) in a private placement to certain accredited investors yielding gross proceeds of $1.0 million before deducting offering expenses. The offering closed on March 21, 2025. |
globenewswire.com |
2025-03-24 09:30:00 |
Czytaj oryginał (ang.) |
| Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership |
BERKELEY HEIGHTS, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicines, today announced a change in control and leadership on February 26, 2025. |
globenewswire.com |
2025-02-27 15:38:00 |
Czytaj oryginał (ang.) |
| Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar |
David Lazar agrees to invest $3.1 million in Preferred Stock and becomes Interim CEO David Lazar agrees to invest $3.1 million in Preferred Stock and becomes Interim CEO |
globenewswire.com |
2025-01-03 11:01:00 |
Czytaj oryginał (ang.) |
| Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs |
BERKELEY HEIGHTS, N.J., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative cancer medicines, today announced that it is in the process of exploring and reviewing strategic alternatives on an expedited basis in order to preserve the Company's cash, including a potential transaction with investor David Lazar of Activist Investing, LLC, which transaction would be subject to the consent of an existing securityholder. |
globenewswire.com |
2024-12-05 18:05:00 |
Czytaj oryginał (ang.) |
| Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds |
BERKELEY HEIGHTS, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative cancer medicines, today announced that it closed its previously announced transaction involving the exercise of certain existing warrants to purchase an aggregate of 4,968,945 shares of its common stock having an original exercise price of $1.36 per share, originally issued in May 2024, at a reduced exercise price of $0.415 per share. The resale of the shares of common stock issued upon exercise of the existing warrants is registered pursuant to an effective registration statement on Form S-1 (File No. 333-279157). |
globenewswire.com |
2024-11-14 18:15:00 |
Czytaj oryginał (ang.) |
| Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds |
BERKELEY HEIGHTS, N.J., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative cancer medicines, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 4,968,945 shares of its common stock having an original exercise price of $1.36 per share, originally issued in May 2024, at a reduced exercise price of $0.415 per share. The resale of the shares of common stock issuable upon exercise of the existing warrants is registered pursuant to an effective registration statement on Form S-1 (File No. 333-279157). |
globenewswire.com |
2024-11-13 14:22:00 |
Czytaj oryginał (ang.) |
| Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update |
BERKELEY HEIGHTS, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines, today announced third quarter financial results and provided a business update. |
globenewswire.com |
2024-11-12 18:45:00 |
Czytaj oryginał (ang.) |
| Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule |
BERKELEY HEIGHTS, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative cancer medicines, today announced that it received a written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) granting the Company an extension until December 24, 2024, to regain compliance with Nasdaq's minimum stockholders equity requirement under Nasdaq Listing Rule 5550(b)(1) (the "Equity Standard Rule"). |
globenewswire.com |
2024-10-24 13:15:00 |
Czytaj oryginał (ang.) |
| Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium |
NEW CLINICAL DATA FROM ONGOING, PHASE 2 STUDY OF ORAL FADRACICLIB AT THE 2024 ENA SYMPOSIUM. Patients preselected for CDKN2A and/or CDKN2B abnormalities |
globenewswire.com |
2024-10-23 13:15:00 |
Czytaj oryginał (ang.) |
| Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium |
Initial safety and efficacy data from fadraciclib monotherapy in patients with advanced solid tumors preselected for CDKN2A and/or CDKN2B abnormalities |
globenewswire.com |
2024-10-09 13:15:00 |
Czytaj oryginał (ang.) |
| Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study |
- Patients are preselected for CDKN2A and/or CDKN2B abnormalities - - Safety and efficacy data to be reported at an upcoming oncology medical conference - BERKELEY HEIGHTS, N.J., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative cancer medicines, today announced that enrollment of 12 patients has been completed as per protocol in Cohort 8 of its Phase 2 stage, proof of concept 065-101 study of fadraciclib (“fadra”), a CDK2/9 inhibitor, in patients with advanced solid tumors and lymphoma. |
globenewswire.com |
2024-09-25 13:15:00 |
Czytaj oryginał (ang.) |
| Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference |
BERKELEY HEIGHTS, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced it will be featured as a presenting company at the H.C. |
globenewswire.com |
2024-09-04 13:15:00 |
Czytaj oryginał (ang.) |
| Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter |
BERKELEY HEIGHTS, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company timely requested a hearing before the Nasdaq Hearings Panel (the “Panel”) and a hearing has been scheduled for October, 15, 2024. |
globenewswire.com |
2024-09-03 13:15:00 |
Czytaj oryginał (ang.) |
| Cyclacel Pharmaceuticals, Inc. (CYCC) Q2 2024 Earnings Call Transcript |
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC ) Q2 2024 Earnings Call Transcript August 14, 2024 4:30 PM ET Company Participants Grace Kim - IR Spiro Rombotis - President and CEO Brian Schwartz - CMO Paul McBarron - EVP, Finance & COO Conference Call Participants Ahu Demir - Ladenburg Thalmann Grace Kim Good afternoon, everyone. And thank you for joining today's conference call to discuss Cyclacel's financial results and business highlights for the second quarter ended June 30, 2024. |
seekingalpha.com |
2024-08-15 00:18:08 |
Czytaj oryginał (ang.) |
| Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results |
BERKELEY HEIGHTS, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter 2024 financial results on Wednesday, August 14, 2024. The Company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day. |
globenewswire.com |
2024-08-07 13:15:00 |
Czytaj oryginał (ang.) |
| Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions |
BERKELEY HEIGHTS, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the receipt of a notice from the European Patent Office of the intention to grant a patent which includes claims to novel pharmaceutical compositions of plogosertib, a PLK1 inhibitor. |
globenewswire.com |
2024-06-26 13:15:00 |
Czytaj oryginał (ang.) |
| Cyclacel's Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting |
- Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific mechanism of action - |
globenewswire.com |
2024-06-04 12:00:00 |
Czytaj oryginał (ang.) |
| Cyclacel Pharmaceuticals, Inc. (CYCC) Q1 2024 Earnings Call Transcript |
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC ) Q1 2024 Earnings Call Transcript May 14, 2024 4:30 PM ET Company Participants Grace Kim - IR Spiro Rombotis - President and CEO Brian Schwartz - CMO Paul McBarron - EVP, Finance & COO Conference Call Participants Ahu Demir - Ladenburg Thalmann Operator Good afternoon and welcome to the Cyclacel Pharmaceuticals First Quarter 2024 Results Conference Call and Webcast. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2024-05-15 00:08:02 |
Czytaj oryginał (ang.) |
| Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results |
BERKELEY HEIGHTS, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce first quarter 2024 financial results on Tuesday, May 14, 2024. The Company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day. |
globenewswire.com |
2024-05-08 13:15:00 |
Czytaj oryginał (ang.) |
| Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules |
BERKELEY HEIGHTS, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it has closed its previously announced private placement for the purchase and sale of 4,968,945 shares of common stock (or pre-funded warrants in lieu thereof), series A warrants to purchase up to 4,968,945 shares of common stock and short-term series B warrants to purchase up to 4,968,945 shares of common stock at a purchase price of $1.61 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants priced at-the-market under Nasdaq rules. The series A warrants and short-term series B warrants have an exercise price of $1.36 per share and are exercisable immediately upon issuance. The series A warrants expire five and one-half years from the date of issuance and the short-term series B warrants expire eighteen months from the date of issuance. |
globenewswire.com |
2024-05-02 20:30:00 |
Czytaj oryginał (ang.) |
| Why Is Cyclacel Pharmaceuticals (CYCC) Stock Up 46% Today? |
Cyclacel Pharmaceuticals (NASDAQ: CYCC ) stock is rocketing higher on Tuesday after the clinical-stage biopharmaceutical company withdrew a proposed public offering. A filing with the Securities and Exchange Commission (SEC) has the company withdrawing its proposed public offering filed in March. |
investorplace.com |
2024-04-30 11:47:07 |
Czytaj oryginał (ang.) |
| Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules |
BERKELEY HEIGHTS, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 4,968,945 shares of common stock (or pre-funded warrant in lieu thereof), series A warrants to purchase up to 4,968,945 shares of common stock and short-term series B warrants to purchase up to 4,968,945 shares of common stock at a purchase price of $1.61 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants in a private placement priced at-the-market under Nasdaq rules. The series A warrants and short-term series B warrants will have an exercise price of $1.36 per share and will be exercisable immediately upon issuance. The series A warrants will expire five and one-half years from the date of issuance and the short-term series B warrants will expire eighteen months from the date of issuance. The private placement is expected to close on or about May 2, 2024, subject to the satisfaction of customary closing conditions. |
globenewswire.com |
2024-04-30 11:00:00 |
Czytaj oryginał (ang.) |